docetaxel

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: docetaxel
• 英文别名: 2'-Epi Docetaxel；[4-acetyloxy-1,9,12-trihydroxy-15-[2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
• 化学式: C₄₃H₅₃NO₁₄
• 分子量: 807.892
• InChiKey: ZDZOTLJHXYCWBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  58
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  224
• 氢给体数：
  5
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  丙烷-2,2-二基双（硫）基]二乙酸 、 docetaxel 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 36.5h， 生成
  参考文献：
  名称：

  POLYMER AND COMPOSITION FROM RENEWABLE SOURCE

  摘要：

  The present invention relates to polymers, compositions thereof, and methods of producing polymers in general. Furthermore, the present invention relates to pharmaceutical compositions and uses of said polymers, compositions and pharmaceutical compositions. More particular, the present invention relates to polymers of jasmine lactone, where pendant groups of said polymers can readily be used for attaching functional moieties comprising active agents. Furthermore, the present invention relates to modified jasmine lactones that can readily be used in methods of producing polymers of the present invention. More particular, the invention relates to polymers from renewable monomers, which can be used in applications such as drug delivery and diagnosis, polymer-drug conjugates, medical devices, cosmetic products, polymers with marker unit, polymers usable as flame retardants, tissue engineering, coatings, paints, lubricants and biodegradable plastics.

  公开号：

  US20220289903A1

文献信息

• FORMULATIONS AND COMPOSITIONS OF DOCETAXEL
  申请人：Zhuhai Beihai Biotech Co., Ltd.

  公开号：US20210023041A1

  公开（公告）日：2021-01-28

  This document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. This document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.
• Docetaxel palmitate liposome and preparation method thereof
  申请人：SHANGHAI WEI ER BIOPHARMACEUTICAL TECH CO., LTD.

  公开号：US20210212947A1

  公开（公告）日：2021-07-15

  The present invention relates to the technical field of medicine, which provides a liposomal docetaxel palmitate formulation and a method for preparing the said formulation. The liposomal docetaxel palmitate formulation contains docetaxel palmitate as the main drug, a chelating agent, lecithin and DSPE-PEG2000. It is characterized in that docetaxel is prepared into a docetaxel palmitate lipophilic prodrug, thus overcoming the defect that docetaxel cannot be processed into liposomes due to poor hydrophilicity and hydrophobicity. The liposome prescription of this invention contains a chelating agent with a substantive effect that can prolong the action time of the drug in the body, improve the anti-tumor effect and be prepared smoothly. Therefore, the chelating agent in the formulation is the core technical feature of the present invention. The purpose of the present invention is to develop a more efficient docetaxel palmitate liposome with no solubilizer so that it can be prepared more easily
• [EN] FORMULATIONS AND COMPOSITIONS OF DOCETAXEL<br/>[FR] FORMULATIONS ET COMPOSITIONS DE DOCÉTAXEL
  申请人：ZHUHAI BEIHAI BIOTECH CO LTD

  公开号：WO2019200084A1

  公开（公告）日：2019-10-17

  This document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. This document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.
• POLYMER AND COMPOSITION FROM RENEWABLE SOURCE
  申请人：ÅBO AKADEMI UNIVERSITY

  公开号：US20220289903A1

  公开（公告）日：2022-09-15

  The present invention relates to polymers, compositions thereof, and methods of producing polymers in general. Furthermore, the present invention relates to pharmaceutical compositions and uses of said polymers, compositions and pharmaceutical compositions. More particular, the present invention relates to polymers of jasmine lactone, where pendant groups of said polymers can readily be used for attaching functional moieties comprising active agents. Furthermore, the present invention relates to modified jasmine lactones that can readily be used in methods of producing polymers of the present invention. More particular, the invention relates to polymers from renewable monomers, which can be used in applications such as drug delivery and diagnosis, polymer-drug conjugates, medical devices, cosmetic products, polymers with marker unit, polymers usable as flame retardants, tissue engineering, coatings, paints, lubricants and biodegradable plastics.